arrow_back Back to App

Faster Generic Drug Review: New FDA Rules

This act aims to speed up the review process for generic drugs by the Food and Drug Administration (FDA). This means citizens could get access to more affordable drug alternatives sooner, potentially lowering healthcare costs and increasing access to important treatments.
Key points
The FDA will be required to determine therapeutic equivalence for generic drugs within 30 days of their approval.
This will accelerate the market entry of more affordable drug versions, potentially reducing healthcare expenses.
The act mandates that the FDA simultaneously review similar drugs, streamlining the process and ensuring consistent decisions.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_1463
Sponsor: Sen. Cassidy, Bill [R-LA]
Process start date: 2021-04-29
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Modernizing Therapeutic Equivalence Rating Determination Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_1463.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-29.

What are the main provisions?

Key points include:

  • The FDA will be required to determine therapeutic equivalence for generic drugs within 30 days of their approval.
  • This will accelerate the market entry of more affordable drug versions, potentially reducing healthcare expenses.
  • The act mandates that the FDA simultaneously review similar drugs, streamlining the process and ensuring consistent decisions.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cassidy, Bill [R-LA].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health